## WHO MDT Regimen for Tuberculoid Leprosy **Key Point:** Tuberculoid leprosy (TT) is treated with a 6-month MDT regimen containing rifampicin, dapsone, and clofazimine. ### Regimen Composition - **Rifampicin:** 600 mg once monthly (supervised) - **Dapsone:** 100 mg daily (unsupervised) - **Clofazimine:** 50 mg daily (unsupervised) ### Duration The standard course is **6 months** with a total of 6 supervised doses of rifampicin. ### Classification Context Tuberculoid leprosy represents the tuberculoid end of the Ridley-Jopling classification, characterized by: - Few bacilli (paucibacillary) - Strong cell-mediated immunity - Limited number of skin lesions (≤5) - Good prognosis with shorter treatment duration **High-Yield:** The 6-month regimen for TT is a frequently tested fact in NEET PG. Remember: **TT = 6 months**, **LL/BL = 12 months**. **Clinical Pearl:** Completion of 6 monthly doses of rifampicin renders the patient non-infectious, regardless of clinical improvement. Patients are declared cured after completing the full course. 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.